Drug Sponsors

Lupin opens Inhalation Research center in Florida

Wednesday, August 12, 2015

Mumbai-based pharmaceutical company Lupin has opened a new Center of Excellence for Inhalation Research in Coral Springs, Fla. Lupin’s new facility will focus on the R&D of inhalation products for asthma, allergic rhinitis, chronic obstructive pulmonary diseases and other lung diseases.

[Read More]

Allergan completes Oculeve acquisition

Wednesday, August 12, 2015

Allergan, a Dublin-based global pharmaceutical company, has completed the acquisition of Oculeve, a development-stage medical device company focused on developing novel treatments for dry-eye disease. Allergan acquired Oculeve for a $125 million upfront payment and commercialization milestone payments related to Oculeve’s lead development program, OD-01. The agreement also includes the acquisition of an additional earlier-stage dry-eye device development program.

[Read More]

Mallinckrodt Pharmaceuticals acquires Therakos

Wednesday, August 12, 2015

Mallinckrodt, a Dublin-based global specialty biopharmaceutical company, and The Gores Group, a global investment firm, have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, a West Chester, Pa.-based immunotherapy company, for about $1.3 billion. Subject to customary closing conditions, the transaction will close by the end of 2015.

[Read More]

OMA restructures after poor trial results

Monday, August 10, 2015

XOMA, a Berkeley, Calif.-based provider of discovery and development of therapeutic antibodies, has reported second-quarter financial results. Due to missed endpoints in a key trial, the company is restructuring.

[Read More]

Eli Lilly to end contract with the UCSD for A4 Alzheimer’s Study

Friday, August 7, 2015

Eli Lilly has notified the University of California, San Diego (UCSD) of its intent to end its contract for the university’s management of the anti-amyloid treatment in asymptomatic Alzheimer’s disease (A4) study. The A4 study is a novel clinical trial testing solanezumab in the preclinical stage of Alzheimer’s disease in older individuals who have evidence of amyloid in their brains on a PET scan, but do not show symptoms of memory impairment. A4 has been managed by the Alzheimer’s Disease Cooperative Study (ADCS) at UCSD. Lilly, the NIH and multiple philanthropic organizations fund the study.

[Read More]

Shire acquires Foresight Biotherapeutics for $300M

Wednesday, August 5, 2015

Shire has acquired New York-based, privately held Foresight Biotherapeutics for $300 million. With the acquisition, Shire acquires the global rights to FST-100 (topical ophthalmic drops combining 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), a therapy in late-stage development for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye. This acquisition further strengthens Shire’s late-stage pipeline, has a clear strategic fit with lifitegrast, which is in late-stage development for treatment of dry-eye disease, and further demonstrates Shire’s commitment to building a leadership position in ophthalmics.

[Read More]

Teva purchases 51% equity share of Immuneering

Wednesday, August 5, 2015

Jerusalem-based Teva Pharmaceutical Industries has entered into an agreement to purchase a 51% equity share of Immuneering, a Cambridge, Mass.-based genomic-analysis company. Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic, and proteomic data that can direct research for enhanced discovery, development and clinical success.

[Read More]